Navigation Links
Rentschler Biotechnologie Extends Capacities for Mammalian Cell Culture Manufacturing
Date:6/20/2008

Laupheim, Germany – June 20, 2008 / b3c newswire /  - Rentschler Biotechnologie, a leading full-service contract manufacturing organization (CMO) for the development and production of biopharmaceuticals in mammalian cells, started operation of a 2,500 L multi-process production suite. Hence, Rentschler Biotechnologie now has nine stand-alone GMP suites with volumes of 30, 250, 500 and 2,500 liters, allowing the production of material for clinical trials and for market supply.

The modern, state-of-the-art 2,500 L bioreactor is designed such that batch, fed-batch, or perfusion cell culture processes can be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.

Using its modern GMP production suites, Rentschler Biotechnologie offers its customers comprehensive services “from gene to drug product”. It is able to develop tailored solutions for each customer through all phases of development and production. Due to its “preferred partnership” agreement with Boehringer Ingelheim, customers requiring higher production capacities than that offered by Rentschler, receive easy access to Boehringer’s large-scale bioreactor volumes of up to 15,000 L.

The global market for biopharmaceutical products is growing constantly and rapidly. As a consequence, since 2002, Rentschler Biotechnologie has invested more than 70 million Euros to enhance its production capacities. Rentschler has thus consolidated its position as a contract manufacturing organization (CMO) for the production of biopharmaceuticals and is now one of three leading European CMOs in this market segment. Since 2001 the number of employees has grown three-fold up to the present 350. 

About Rentschler Biotechnologie – www.rentschler.de
Rentschler Biotechnologie GmbH is part of the privately held Rentschler Group based in Laupheim, Germany. As an international full-service contract manufacturer with a highly skilled staff of 350, Rentschler Biotechnologie has substantial long-term experience in the development, production and approval of cell culture-derived biopharmaceuticals in compliance with international GMP standards. Regulatory advice and fill & finish are part of the company's service range.

Contact:
Dr. Wieland Wolf
Dr. Rentschler Holding GmbH & Co. KG
Phone: +49 (0)7392-701-0
e-mail: presse@rentschler.de

Media contact:
Friederike Braun
Phone: +49 (0)7392 701–555
e-mail: friederike.braun@rentschler.de


'/>"/>
www.b3c.de

Related biology technology :

1. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
2. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
3. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
8. Amyris Biotechnologies Announces $70 Million Series B Round
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
11. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):